Disease & Solutions Products Professional Education Innovation Ecosystem Investor Relations News Careers About Us
You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Milestones
Corporate Overview Milestones Leadership Team Corporate Social Responsibility Awards and Recognitions Contact Us
2022
2022-05-31 17:59:57

The Company proposed the establishment of the Interventional Medtech Institute, an Industrial Research Institute in Suzhou. 

The Company signed an exclusive license and technology transfer agreement with JenaValve Technology for TAVR products for aortic regurgitation.

The Company obtained NMPA's approval for Syphonet® Stent Retriever、Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilation Catheter .

The Company's TaurusNXT® Transcatheter Aortic Valve Replacement System and HighLife® TSMVR were approved by the NMPA as an innovative medical device.

The Company completed the the First-in-human clinical trial of the HighLife® TSMVR and GeminiOne TEER.

Prev：2013
Next：2023
Top